Please ensure Javascript is enabled for purposes of website accessibility

How Moderna Went From Coronavirus Sequence to a Phase-1-Ready Vaccine Candidate in 42 Days

By Brian Orelli, PhD – Aug 5, 2020 at 8:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech got a little help from Amazon's AWS.

Moderna (MRNA 0.15%), one of the leaders in the race to develop a coronavirus vaccine, was able to take the initial coronavirus sequence and get a vaccine candidate, mRNA-1273, ready for a phase 1 clinical trial in just 42 days.

The biotech's use of Amazon Web Services (AWS), the cloud-based computing service run by Amazon (AMZN -1.57%), enabled this quick development. Moderna runs its Drug Design Studio on AWS, which allows it to design its mRNA drug candidates quickly.

The potential drugs are further analyzed using machine learning to optimize the sequence for manufacturing. And with Moderna's manufacturing systems running on AWS, converting the vaccine sequences to physical mRNA vaccine candidates ready for preclinical testing was a straightforward process.

Gloved hands administering an injection to a shoulder.

Image source: Getty Images.

Of course, Amazon can't take all the credit. While AWS undoubtedly helped speed up the process, Moderna's mRNA platform played a big role in the biotech developing a candidate so quickly. Protein-based vaccines are lagging behind mRNA vaccine-makers, such as Moderna and BioNTech (BNTX 0.96%), simply because protein-based drugs take longer to design and optimize -- especially at the manufacturing step -- as the proteins have more complex structures than mRNAs.

Rather than dealing with the challenging protein step, Moderna and BioNTech let the patients' cells translate the mRNA sequence into a protein that can elicit an immune reaction just like injecting the protein directly into the patient.

If mRNA-1273 passes its ongoing phase 3 clinical trial, AWS could come into play again. As Moderna ramps up manufacturing capabilities, AWS will allow for a quick technology transfer of its manufacturing model into its partners' facilities.

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Brian Orelli, PhD has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Amazon and recommends the following options: long January 2022 $1920 calls on Amazon and short January 2022 $1940 calls on Amazon. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amazon.com, Inc. Stock Quote
Amazon.com, Inc.
AMZN
$113.00 (-1.57%) $-1.80
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$118.25 (0.15%) $0.18
BioNTech SE Stock Quote
BioNTech SE
BNTX
$134.88 (0.96%) $1.28

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.